[1]     Lindor NM，McMaster ML，Lindor CJ，et al.Concise handbook of familial cancer susceptibility syndromes-second edition[J].J National Cancer Institute Monographs，2008，38：1-93.



[2]    Li WF，Hu Z，Rao NY，et al.The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality：two recurrent mutations were identified[J].Breast Cancer Res Treatment，2008，110（1）：99-109.



[3]    Li J，Meeks H，Feng BJ，et al.Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families[J].J Med Genet，2016，53（1）：34-42.



[4]     Helder-Woolderink JM，Blok EA，Vasen HF，et al.Ovarian cancer in Lynch syndrome; a systematic review[J].Eur J Cancer，2016，55：65-73.



[5]    Kurman RJ，Shih LM.Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm[J].Human Pathol，2011，42（7）：918-931.



[6]     Hall MJ，Obeid EI，Schwartz SC，et al.Genetic testing for hereditary cancer predisposition：BRCA1/2，lynch syndrome，and beyond[J].Gynecol Oncol，2016[Epub head of print].



[7]     Lancaster JM，Powell CB，Kauff ND，et al.Society of gynecologic oncologists education committee statement on risk assessment for inherited gynecologic cancer predispositions[J].Gynecol Oncol，2007，107（2）：159-162.



[8]     Walker JL，Powell CB，Chen LM，et al.Society of gynecologic oncology recommendations for the prevention of ovarian cancer[J].Cancer，2015[Epub head of print].



（2016-02-20收稿）